Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

A Phase II, multisite, open-label, single arm trial of BNT327 in combination with docetaxel in second-line stage IV or recurrent non-small cell lung cancer (NSCLC) following chemoimmunotherapy

A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC)